EGFR and lung cancer: Platinum-based chemotherapy is the recommended first-line treatment for the majority of advanced inoperable lung cancers [4, 5], with the exception of inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase as the first-line therapy for patients with an activating EGFR mutation [5, 6].